Save
esh.org
Genomic landscape of Waldenström’s macroglobulinemia
ESH eLearning, Steven Treon, 233978
POEMS syndromes
ESH eLearning, Arnaud Jaccard, 233979
How to judge the value of a clinical trial: HR, median PFS, p-value
ESH eLearning, Robert Hills, 233980
Real-world evidence –What is it and what can it tell us?
ESH eLearning, Kwee Yong, 233981
Optimal cost/safety/efficacy/QOL ration
ESH eLearning, Jean-Luc Harousseau, 233982
New generation sequencing in multiple myeloma
ESH eLearning, Nikhil Munshi, 233973
When and how to treat first relapse according to the guidelines
ESH eLearning, Meletios A Dimopoulos, 233974
New drugs, new immune therapies, new targeted therapies
ESH eLearning, Enrique Ocio, 233975
Adoptive cell therapy in multiple myeloma
ESH eLearning, Jesus Berdeja, 233976
Future combinations for the treatment of MM
ESH eLearning, Kenneth C. Anderson, 233977
From MGUS to MM: Do all clones take the same road?
ESH eLearning, Madhav Dhodapkar, 233965
Leukemic stem cells modulate the bone marrow microenvironment
ESH eLearning, María-Victoria Mateos, 233966
Genetics and risk assessment (including clonal evolution and clinical implications in terms of risk assessment)
ESH eLearning, Hervé Avet-Loiseau, 233967
Primary plasma cell leukaemia and extramedullary disease
ESH eLearning, Niels Van de Donk, 233968
Geriatric assessment: is it required?
ESH eLearning, Alessandra Larocca, 233969
European guidelines
ESH eLearning, Sonja Zweegman, 233970
Ongoing trials for newly diagnosed patients not eligible for stem cell transplantation, and frontline treatment when new drugs are not available
ESH eLearning, Kwee Yong, 233971
Induction therapy: triplet, quadruplet?
ESH eLearning, Philippe Moreau, 233972
Geriatric assessment in multiple myeloma: is it required?
ESH eLearning, Alessandra Larocca, 234000
MRD as a response assessment in elderly multiple myeloma
ESH eLearning, Alessandra Larocca, 234001
Vaccines to prevent progression or relapse in multiple myeloma
ESH eLearning, Ann van de Velde, 234002
How do we define a ‘cure’ in myeloma?
ESH eLearning, Annemiek Broijl, 234003
Treatment options for high-risk myeloma
ESH eLearning, Annemiek Broijl, 234004
Smoldering myeloma treatment landscape & MRD negativity
ESH eLearning, Annemiek Broijl, 234005
Dendritic cell vaccine for MM: trial updates with maintenance & checkpoint inhibitor pidilizumab
ESH eLearning, David Avigan, 234006
Investigating vaccines for hem-onc: key questions
ESH eLearning, David Avigan, 234007
What is the role of PET/CT in myeloma management?
ESH eLearning, Elena Zamagni, 234008
Where will we be in MM management 5 years from now?
ESH eLearning, Elena Zamagni, 234009
A host of promising agents for myeloma: melflufen, filanesib, trametinib, selinexor
ESH eLearning, Enrique Ocio, 234010
Immunotherapeutics against multiple myeloma: it's all about BCMA
ESH eLearning, Enrique Ocio, 234011
Are BCL2 and MCL1 inhibitors the key against myeloma?
ESH eLearning, Enrique Ocio, 234012
The evolving imaging of multiple myeloma
ESH eLearning, Evangelos Terpos, 234013
Real world data: bortezomib-based therapy for R/R myeloma
ESH eLearning, Evangelos Terpos, 234014
Real world data for len/dex in second-line myeloma: what does this tell us?
ESH eLearning, Evangelos Terpos, 234015
Double-blind trial of denosumab vs. zoledronic acid for bone disease in NDMM
ESH eLearning, Evangelos Terpos, 234016
Treatment sequencing in multiple myeloma: a multitude of options
ESH eLearning, Heinz Ludwig, 234017
Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
ESH eLearning, Heinz Ludwig, 234018
Smoldering multiple myeloma: what is the current definition & new screening programme
ESH eLearning, Irene Ghobrial, 234019
Opinion: MRD sequencing test approval in multiple myeloma
ESH eLearning, Irene Ghobrial, 234020
CAR T-cells for multiple myeloma: update & what's in store for ASH 2018
ESH eLearning, Jesus Berdeja, 234021
Toxicity profile for CAR T-cells in multiple myeloma
ESH eLearning, Jesus Berdeja, 234022
MRD and disease eradication in myeloma
ESH eLearning, Jesús San Miguel, 234023
Early detection and intervention in myeloma: a critical point
ESH eLearning, Jesús San Miguel, 234024
Continuous vs. fixed duration therapy for multiple myeloma?
ESH eLearning, Jesús San Miguel, 234025
Future treatment combinations for myeloma
ESH eLearning, Kenneth Anderson, 234026
MRD detection in myeloma: approval of NGS assay & questions for the clinic
ESH eLearning, Kenneth Anderson, 234027
Frontline transplant-ineligible MM treatment
ESH eLearning, Kwee Yong, 234028
Combining bortezomib and lenalidomide-based regimens for frontline MM
ESH eLearning, Kwee Yong, 234029
Real world evidence: what is it and what can it tell us?
ESH eLearning, Kwee Yong, 234030
How should smoldering multiple myeloma be monitored?
ESH eLearning, María-Victoria Mateos, 234031
Update on recent smoldering multiple myeloma trials
ESH eLearning, María-Victoria Mateos, 234032
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
ESH eLearning, María-Victoria Mateos, 234033
Opinion: EU approval of daratumumab plus VMP for frontline transplant-ineligible multiple myeloma
ESH eLearning, María-Victoria Mateos, 234034
Plasma cell leukemia and extramedullary disease in multiple myeloma
ESH eLearning, Niels van de Donk, 234035
Daratumumab in myeloma update: expanding indications
ESH eLearning, Niels van de Donk, 234036
A novel mechanism of action for daratumumab in myeloma
ESH eLearning, Niels van de Donk, 234037
CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079
ESH eLearning, Niels van de Donk, 234038
MRD negativity using deep sequencing is a major prognostic factor in myeloma
ESH eLearning, Nikhil Munshi, 234039
MRD sequencing test approved for MM in the US
ESH eLearning, Nikhil Munshi, 234040
Genomics shed light on targeted treatment for myeloma
ESH eLearning, Nikhil Munshi, 234041
Frontline treatment of transplant-ineligible MM: a changing landscape
ESH eLearning, Noopur Raje, 234042
Quadruplet regimens and antibodies for newly diagnosed multiple myeloma
ESH eLearning, Noopur Raje, 234043
CAR T-cells for myeloma: an update
ESH eLearning, Noopur Raje, 234044
PVX-410 vaccine for smoldering myeloma
ESH eLearning, Noopur Raje, 234045
Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)
ESH eLearning, Noopur Raje, 234046
Judging the value of a clinical trial in hem-onc
ESH eLearning, Robert Hills, 234047
Opinion: value of MRD as an endpoint in hem-onc clinical trials
ESH eLearning, Robert Hills, 234048
UK NCRI AML17 trial update: everolimus addition for consolidation
ESH eLearning, Robert Hills, 234049
Monoclonal antibodies: current and future potential
ESH eLearning, Saad Usmani, 234050
Targeting BCMA with bispecific antibodies in R/R myeloma
ESH eLearning, Saad Usmani, 234051
Updated POLLUX results for early relapsed myeloma patients
ESH eLearning, Saad Usmani, 234052
Whole genome sequencing opens door for targeted Waldenström’s therapy
ESH eLearning, Steven Treon, 234053
Exploring treatment options against different Waldenström’s mutations
ESH eLearning, Steven Treon, 234054
Mapping the genomic landscape of Waldenström’s Macroglobulinemia
ESH eLearning, Steven Treon, 234055
How to predict response in silico and in vitro?
ESH eLearning, David Weinstock, 234062
Design of innovative clinical trials: still a role for phase III trials?
ESH eLearning, Andrew Davies, 234063
Minimal biological measurement requirements for DLBCL: What do clinicians need to have measured?
ESH eLearning, Lisa RIMSZA, 234061
Which pro-survival BCL-2 family member should be targeted for the treatment of which type of leukaemia or lymphoma
ESH eLearning, Andreas STRASSER, 234057
Targeting MALT1 signaling: preclinical data and perspectives in the clinic
ESH eLearning, Daniel KRAPMANN, 234058
The genetic landscape of MCL – more than CyclinD1?
ESH eLearning, Eias CAMPO, 234059
T-NHL: novel targets and therapies - How can we move forward?
ESH eLearning, Norbert SCHMITZ, 234060
Managing CML in emerging regions: some problems and perspectives
ESH eLearning, Hemant Malhotra, 234664
Long-term survival of patients with chronic phase chronic myeloid leukemia who received autologous stem cell transplantation and further exposed to tyrosine kinase inhibitors
ESH eLearning, Mauricette Michallet, 234801
Low-intensity TKI-based therapy for Ph+ ALL
ESH eLearning, Hervé Dombret, 234568
Impact of kinase domain mutations on second line nilotinib therapy In CML chronic phase – Real world data from a developing country perspective
ESH eLearning, Shinto Francis Thekkudan, 234569
Are TKI really safe?
ESH eLearning, Carlo Gambacorti-Passerini, 234570
Long-term impact of early and deeper molecular response in newly diagnosed CML-CP patients receiving radotinib: three years follow-up of rerise study
ESH eLearning, Young Rok Do, 234571
Molecular milestones using the BCR-ABL1 qPCR level and doubling time after imatinib discontinuation to predict successful treatment-free remission: treatment-free remission accomplished by dasatinib (TRAD) trial
ESH eLearning, Dennis Kim, 234573
Stem cell transplant for Ph+ ALL: who, when, how
ESH eLearning, Federico Lussana, 234797
How to identify and manage Ph-like ALL
ESH eLearning, Sarah Tasian, 234798
What prevents the disease from relapsing after TKI discontinuation
ESH eLearning, Satu Mustjoki, 234803
ELN and real-word treatment algorithms for MPNs
ESH eLearning, Giuseppe Saglio, 234566
The association of transposable elements with chronic myeloid leukemia supports an assumption that non-coding variable regions of the human genome may play a role in hematological malignancies
ESH eLearning, Jitka Koblihova, 234567
HMGCLL1 Is a predictive germline biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia
ESH eLearning, Dennis Kim, 234572
Bcl-2 and its inhibition in leukemia
ESH eLearning, Marina Konopleva, 234637
Novel approaches to monitor MPN
ESH eLearning, Jerry Radich, 234799
Resistance and progression to TKI: not just mutations
ESH eLearning, Jerry Radich, 234800
Single-molecule sequencing reveals patterns of pre-existing drug resistance that suggest treatment strategies in Philadelphia-positive leukemias
ESH eLearning, Justin Pritchard, 234802
Why the fuss over CML stem cells ?
ESH eLearning, Robert Peter Gale, 234565
Mastocytosis
ESH eLearning, Jason Gotlib, 219417

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings